Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics

PLoS Computational Biology

Volumn 11, Issue 11, 2015, Pages

  Lovera, Silvia ^a   Morando, Maria ^b   Pucheta Martinez, Encarna ^a   Martinez Torrecuadrada, Jorge L ^c   Saladino, Giorgio ^a   Gervasio, Francesco L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c Structural Biology and Biocomputing Programme   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BINDING ENERGY; DIAGNOSIS; DISEASES; DRUG THERAPY; ENZYMES; FREE ENERGY;

ANTI-CANCER THERAPIES; CATALYTIC DOMAINS; CHRONIC MYELOID LEUKEMIAS; CONFORMATIONAL DYNAMICS; DRUG-RESISTANCE; FUSION PROTEINS; IMATINIB; KINASE DOMAINS; MOLECULAR UNDERSTANDING; TYROSINE KINASE;

MOLECULAR DYNAMICS;

PROTEIN TYROSINE KINASE; BCR ABL PROTEIN; IMATINIB;

ALPHA HELIX; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CALCULATION; CANCER RESISTANCE; DRUG BINDING; ENTHALPY; IC50; IN VITRO STUDY; LEUKEMIA; MATHEMATICAL ANALYSIS; MICROCALORIMETRY; MOLECULAR DYNAMICS; MUTAGENESIS; THERMODYNAMICS; BIOLOGY; CHEMISTRY; CHRONIC MYELOID LEUKEMIA; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; SITE DIRECTED MUTAGENESIS;

COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR DYNAMICS SIMULATION; MUTAGENESIS, SITE-DIRECTED; THERMODYNAMICS;

EID: 84949294800     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004578     Document Type: Article

References (68)

1. Capdeville R, Buchdunger E, Zimmermann J, Matter A, Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1(7):493–502. 12120256
2. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006 Sep;108(6):1809–20. doi: 10.1182/blood-2006-02-005686 16709930
3. Kantarjian H, O’Brien S, Garcia-Manero G, Faderl S, Ravandi F, Jabbour E, et al. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer. 2012;118(12):3116–22. doi: 10.1002/cncr.26568 22370904
4. Hantschel O, Superti-Furga G, Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol. 2004 Jan;5(1):33–44. doi: 10.1038/nrm1280 14708008
5. Deininger M, Buchdunger E, Druker BJ, The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105(7):2640–53. doi: 10.1182/blood-2004-08-3097 15618470
6. Barouch-Bentov R, Sauer K, Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs. 2011;20(2):153–208. doi: 10.1517/13543784.2011.546344 21235428
7. Dixit A, Verkhivker GM, Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. PLoS Comput Biol. 2009;5(8):e1000487. doi: 10.1371/journal.pcbi.1000487 19714203
8. Dixit A, Verkhivker GM, Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases. PLoS Comput Biol. 2011;7(10):e1002179. doi: 10.1371/journal.pcbi.1002179 21998569
9. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876–80. doi: 10.1126/science.1062538 11423618
10. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA. 2008;105(6):2070–5. doi: 10.1073/pnas.0709662105 18227510
11. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ, Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol. 2008 Oct;15(10):1109–1118. doi: 10.1038/nsmb.1486 18794843
12. Sutto L, Gervasio FL, Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase. Proc Natl Acad Sci USA. 2013;110(26):10616–21. doi: 10.1073/pnas.1221953110 23754386
13. Bunney TD, Wan S, Thiyagarajan N, Sutto L, Williams SV, Ashford P, et al. The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study. EBioMedicine. 2015 Mar;2(3):194–204. doi: 10.1016/j.ebiom.2015.02.009 26097890
14. Wilson C, Agafonov RV, Hoemberger M, Kutter S, Zorba A, Halpin J, et al. Kinase dynamics. Using ancient protein kinases to unravel a modern cancer drug’s mechanism. Science. 2015 Feb;347(6224):882–886. doi: 10.1126/science.aaa1823 25700521
15. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117–125. doi: 10.1016/S1535-6108(02)00096-X 12204532
16. Azam M, Latek RR, Daley GQ, Mechanisms of Autoinhibition and STI-571 / Imatinib Resistance Revealed by Mutagenesis of BCR-ABL. Cell. 2003;112:831–843. doi: 10.1016/S0092-8674(03)00190-9 12654249
17. Azam M, Nardi V, Shakespeare WC, Metcalf CA, Bohacek RS, Wang Y, et al. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci USA. 2006;103(24):9244–9. doi: 10.1073/pnas.0600001103 16754879
18. Zheng W, Brooks BR, Thirumalai D, Low-frequency normal modes that describe allosteric transitions in biological nanomachines are robust to sequence variations. Proc Natl Acad Sci USA. 2006;103(20):7664–9. doi: 10.1073/pnas.0510426103 16682636
19. Kumar S, Ma B, Tsai CJ, Sinha N, Nussinov R, Folding and binding cascades: dynamic landscapes and population shifts. Protein Sci. 2000;9(1):10–9. doi: 10.1110/ps.9.1.10 10739242
20. Foda ZH, Shan Y, Kim ET, Shaw DE, Seeliger MA, A dynamically coupled allosteric network underlies binding cooperativity in Src kinase. Nat Comm. 2015;6:5939. doi: 10.1038/ncomms6939
21. Liu Y, Gray NS, Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol. 2006;2(7):358–64. doi: 10.1038/nchembio799 16783341
22. Engen JR, Wales TE, Hochrein JM, Meyn Ma, Banu Ozkan S, Bahar I, et al. Structure and dynamic regulation of Src-family kinases. Cell Mol Life Sci. 2008;65(19):3058–73. doi: 10.1007/s00018-008-8122-2 18563293
23. Shan Y, Seeliger MA, Eastwood MP, Frank F, Xu H, Jensen MO, et al. A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci USA. 2009;106(1):139–144. doi: 10.1073/pnas.0811223106 19109437
24. Nagar B, Bornmann WG, Pellicena P, Pd MI, Sti I, Schindler T, et al. Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small. Cancer. 2002;p. 4236–4243.
25. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, et al. Article Activation State-Dependent Binding of Small Molecule Kinase Inhibitors: Structural Insights from Biochemistry. Chem Biol. 2010;17(11):1241–1249. doi: 10.1016/j.chembiol.2010.09.010 21095574
26. Seeliger Ma, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J, c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure. 2007;15(3):299–311. doi: 10.1016/j.str.2007.01.015 17355866
27. Aleksandrov A, Simonson T, Molecular Dynamics Simulations Show That Conformational Selection Governs the Binding Preferences of Imatinib for Several Tyrosine Kinases. J Biol Chem. 2010 Apr;285(18):13807–13815. doi: 10.1074/jbc.M110.109660 20200154
28. Lin YL, Meng Y, Jiang W, Roux B, Explaining why Gleevec is a specific and potent inhibitor of Abl kinase. Proc Natl Acad Sci USA. 2013 Jan;110(5):1664–1669. doi: 10.1073/pnas.1214330110 23319661
29. Lovera S, Sutto L, Boubeva R, Scapozza L, Dölker N, Gervasio FL, The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation. J Am Chem Soc. 2012;134(5):2496–9. doi: 10.1021/ja210751t 22280319
30. Sali A, Blundell TL, Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993;234(3):779–815. doi: 10.1006/jmbi.1993.1626 8254673
31. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C, Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins: Struct Funct Bioinf. 2006;65:712–725. doi: 10.1002/prot.21123
32. Lindorff-larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins. 2010;78(8):1950–8. doi: 10.1002/prot.22711 20408171
33. Best RB, Hummer G, Optimized molecular dynamics force fields applied to the helix-coil transition of polypeptides. J Phys Chem B. 2009;113(26):9004–15. doi: 10.1021/jp901540t 19514729
34. Jorgensen WL, Transferable intermolecular potential functions for water, alcohols, and ethers. Application to liquid water. J Am Chem Soc. 1981;103(2):335–340. doi: 10.1021/ja00392a016
35. Harvey MJ, Giupponi G, De Fabritiis G, ACEMD: Accelerating Biomolecular Dynamics in the Microsecond Time Scale. J Chem Theory Comput. 2009;5(6):1632–1639. doi: 10.1021/ct9000685
36. Bussi G, Gervasio FL, Laio A, Parrinello M, Free-energy landscape for beta hairpin folding from combined parallel tempering and metadynamics. J Am Chem Soc. 2006;128(41):13435–41. doi: 10.1021/ja062463w 17031956
37. Barducci A, Bussi G, Parrinello M, Well-tempered metadynamics: A smoothly converging and tunable free-energy method. Phys Rev Lett. 2008;100(2):020603. doi: 10.1103/PhysRevLett.100.020603 18232845
38. Bonomi M, Parrinello M, Enhanced Sampling in the Well-Tempered Ensemble. Phys Rev Lett. 2010;104(19):1–4. doi: 10.1103/PhysRevLett.104.190601
39. Deighan M, Bonomi M, Pfaendtner J, Efficient Simulation of Explicitly Solvated Proteins in the Well-Tempered Ensemble. J Chem Theory Comput. 2012; 8(7):2189–2192. doi: 10.1021/ct300297t
40. Dölker N, Górna MW, Sutto L, Torralba AS, Superti-Furga G, Gervasio FL, The SH2 Domain Regulates c-Abl Kinase Activation by a Cyclin-Like Mechanism and Remodulation of the Hinge Motion. PLoS Comput Biol. 2014;10(10):e1003863. doi: 10.1371/journal.pcbi.1003863 25299346
41. Marino KA, Sutto L, Gervasio FL, The Effect of a Widespread Cancer-Causing Mutation on the Inactive to Active Dynamics of the B-Raf Kinase. J Am Chem Soc. 2015 Apr;137:5280–5283. doi: 10.1021/jacs.5b01421 25868080
42. Papaleo E, Sutto L, Gervasio FL, Lindorff-Larsen K, Conformational Changes and Free Energies in a Proline Isomerase. J Chem Theory Comput. 2014;10(9):4169–4174. doi: 10.1021/ct500536r
43. Hess B, Kutzner C, Spoel DVD, Lindahl E, van Der Spoel D, Gromacs 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput. 2008;4(3):435–447. doi: 10.1021/ct700301q
44. Bonomi M, Branduardi D, Bussi G, Camilloni C, Provasi D, Raiteri P, et al. PLUMED: a portable plugin for free-energy calculations with molecular dynamics. Comp Phys Comm. 2009;180:1961–1972. doi: 10.1016/j.cpc.2009.05.011
45. Bussi G, Donadio D, Parrinello M, Canonical sampling through velocity rescaling. J Chem Phys. 2007;126:14101. doi: 10.1063/1.2408420
46. Tiwary P, Parrinello M, A time-independent free energy estimator for metadynamics. J Phys Chem B. 2015 Jan;119(3):736–742. doi: 10.1021/jp504920s 25046020
47. Branduardi D, Gervasio FL, Parrinello M, From A to B in free energy space. J Chem Phys. 2007 Feb;126(5):054103. doi: 10.1063/1.2432340 17302470
48. Jo S, Chipot C, Roux B, Efficient Determination of Relative Entropy Using Combined Temperature and Hamiltonian Replica-Exchange Molecular Dynamics. J Chem Theory Comput. 2015;11(5):2234–2244. doi: 10.1021/ct501034w
49. Frisch MJ, et al. Gaussian 03, Revision C.02;. Gaussian, Inc., Wallingford, CT, 2004.
50. Saladino G, Gervasio FL, New insights in protein kinase conformational dynamics. Curr Tomp Med Chem. 2012 Sep;12(17):1889–1895. doi: 10.2174/156802612804547407
51. Cavalli A, Spitaleri A, Saladino G, Gervasio FL, Investigating Drug–Target Association and Dissociation Mechanisms Using Metadynamics-Based Algorithms. Acc Chem Res. 2015 Feb;48(2):277–285. doi: 10.1021/ar500356n 25496113
52. Masetti M, Cavalli A, Recanatini M, Gervasio FL, Exploring Complex Protein-Ligand Recognition Mechanisms with Coarse Metadynamics. The journal of physical chemistry B. 2009;113(14):4807–4816. doi: 10.1021/jp803936q 19298042
53. Campos-Olivas R, Marenchino M, Scapozza L, Gervasio FL, Backbone assignment of the tyrosine kinase Src catalytic domain in complex with imatinib. Biomol NMR Assign. 2011 Oct;5(2):221–4. doi: 10.1007/s12104-011-9304-7 21523440
54. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003 Jul;102(1):276–83. doi: 10.1182/blood-2002-09-2896 12623848
55. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295(1):139–45. 10991971
56. Buchdunger E, Matter A, Druker BJ, Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta. 2001;1551(1):M11–8. 11553417
57. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB, Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives. Bioorg Med Chem Lett. 1997;7(2):187–192. doi: 10.1016/S0960-894X(96)00601-4
58. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J, Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (80-). 2000;289(5486):1938–42. doi: 10.1126/science.289.5486.1938
59. Bradeen HA, Eide CA, O’Hare T, Johnson KJ, Willis SG, Lee FY, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108(7):2332–2338. doi: 10.1182/blood-2006-02-004580 16772610
60. Young Ma, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J, Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell. 2001;105(1):115–26. doi: 10.1016/S0092-8674(01)00301-4 11301007
61. Zhang J, Adrián FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010 Jan;463(7280):501–6. doi: 10.1038/nature08675 20072125
62. Seeliger Ma, Ranjitkar P, Kasap C, Shan Y, Shaw DE, Shah NP, et al. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 2009;69(6):2384–92. doi: 10.1158/0008-5472.CAN-08-3953 19276351
63. Shan Y, Eastwood MP, Zhang X, Kim ET, Arkhipov A, Dror RO, et al. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell. 2012;149(4):860–870. doi: 10.1016/j.cell.2012.02.063 22579287
64. Meng Y, Roux B, Locking the Active Conformation of c-Src Kinase through the Phosphorylation of the Activation Loop. J Mol Biol. 2014;426:423–435. doi: 10.1016/j.jmb.2013.10.001 24103328
65. Tam IYS, Leung ELH, Tin VPC, Chua DTT, Sihoe ADL, Cheng LC, et al. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther. 2009;8(8):2142–51. doi: 10.1158/1535-7163.MCT-08-1219 19671738
66. Miyashita O, Onuchic JN, Wolynes PG, Nonlinear elasticity, proteinquakes, and the energy landscapes of functional transitions in proteins. Proc Natl Acad Sci USA. 2003;100(22):12570–12575. doi: 10.1073/pnas.2135471100 14566052
67. Shan Y, Arkhipov a, Kim ET, Pan aC, Shaw DE, Transitions to catalytically inactive conformations in EGFR kinase. Proc Natl Acad Sci USA. 2013;110(18): 7270–7275. doi: 10.1073/pnas.1220843110 23576739
68. Yang LJ, Zou J, Xie HZ, Li LL, Wei YQ, Yang SY, Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl. PLoS ONE. 2009;4(12):e8470. doi: 10.1371/journal.pone.0008470 20041122